Skip to content

Sedation Protocols and Skeletal Muscle Metabolism in Mechanical Ventilated Patients

The Effect of Different Sedation Protocols on Skeletal Muscle Metabolism in Mechanical Ventilated Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03402113
Enrollment
360
Registered
2018-01-18
Start date
2017-12-20
Completion date
2019-01-31
Last updated
2018-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercatabolism, Sedative, Hypnotic, or Anxiolytic Use Disorders

Brief summary

To investigate the effects of different sedation protocols on skeletal muscle metabolism in mechanical ventilated patients in ICU. Mechanical ventilated patients who are anticipated to stay in ICU for more than 5 days are enrolled and randomly assigned to the following three groups, interventional group(dexmedetomidine), control group(midazolam) and no sedation group. Serum, CT scan of intercostal muscles, ultrasound evaluation of quadriceps femoris are obtained.

Interventions

DRUGDexmedetomidine

consistent infusion at a loading dose of 0.15ug/kg/h, increased by 0.15ug/kg/h, with a maximum dose of 1.5ug/kg/h.

DRUGMidazolam

consistent infusion at a loading dose of 1mg/h, increased by 1mg/h, with a maximum dose of 10mg/h.

Sponsors

Chinese Medical Association
Lead SponsorNETWORK

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* mechanical ventilated for more than 48h * 18-80 years * stay in ICU for more than 5 days

Exclusion criteria

* already participated in other clinical trials * pregnancy or lactation * lower limb amputation * primary neuro-muscular disease * disseminated tumor or accepted special therapy * alcohol abuse * severe liver dysfunction(Child-Push C) * unstable angina/acute myocardial infarction * heart rates\<50bpm * all kinds dialysis * severe burn * epidural anesthesia * severe neurological disease(acute stroke, uncontrollable epilepsy, severe dementia, etc)

Design outcomes

Primary

MeasureTime frameDescription
acute muscle wastingFrom date of randomization to extubation,up to 7 daysmeasured by 3-MH release in serum

Secondary

MeasureTime frameDescription
28-day mortalityFrom date of randomization to date of death from any cause,up to 28 daysdeath rate within 28 days after mechanical ventilation
length of ICU stayFrom date of randomization to date of to discharge or death,up to 28 daystime from enrollment to discharge or die

Countries

China

Contacts

Primary ContactWenkui Yu, Ph.D
yudrnj@163.com13701582986
Backup ContactQin Gu, Master
icuguqin@sina.com13705150348

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026